Sherbrooke Park Advisers LLC Acquires 3,162 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Sherbrooke Park Advisers LLC raised its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 10.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,311 shares of the company’s stock after purchasing an additional 3,162 shares during the quarter. Sherbrooke Park Advisers LLC’s holdings in 10x Genomics were worth $478,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after acquiring an additional 1,299 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter worth about $52,000. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after acquiring an additional 4,324 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

TXG has been the subject of a number of research analyst reports. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on shares of 10x Genomics from $18.00 to $15.00 and set a “buy” rating for the company in a report on Monday, May 12th. UBS Group decreased their price objective on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.42.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. The trade was a 1.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. The trade was a 0.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 9.39% of the company’s stock.

10x Genomics Stock Performance

NASDAQ:TXG opened at $9.39 on Friday. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $25.55. The firm has a market cap of $1.15 billion, a P/E ratio of -6.18 and a beta of 1.94. The firm has a 50-day simple moving average of $8.77 and a 200-day simple moving average of $12.33.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same quarter in the previous year, the business posted ($0.50) EPS. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.